Drug Trial Radar · NCT06205706
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Actual
Start
Dec 4, 2023
Primary completion
Jul 14, 2027
Study completion Nov 7, 2028
Sponsor
- Lead sponsor
- BioInvent International ABIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with pembrolizumab every 3 weeks.
Conditions
- Solid Tumors
- Non Small Cell Lung Cancer
- Hepatocellular Carcinoma
Interventions
BI-1910Drug
BI-1910 administered as a flat-dose IV infusion once every 3 weeks
PembrolizumabDrug
Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse events (AEs)Time frame: From the start of the study treatment for up to 2 years and 90 days.
- Occurrence of serious adverse events (SAEs)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Frequency of AEs leading to discontinuation of study treatmentTime frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Frequency of dose interruptions and dose reductions.Time frame: From the start of the study treatment for up to 2 years
- Changes from baseline in laboratory parametersTime frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Changes from baseline in temperature (C or F)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Changes from baseline in Respiratory Rate (Breaths/Min)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Changes from baseline in Blood Pressure (mmHg)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Changes from baseline in O2 Saturation (%)Time frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Changes from baseline in weightTime frame: From screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
- Occurrence of dose limiting toxicities (DLTs)Time frame: During phase 1 Part A: from the first dose of BI-1910 for 21 days. During phase 1 part B: from the first dose of BI-1910 for 42 days.
- identification of dose/dose range fulfilling favorable PK and pharmacodynamic profile, with acceptable safetyTime frame: During phase 2a from screening for up to 28 days, throughout treatment for up to 2 years and through follow-up for up to 90 days
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Universitätsklinikum Essen
Essen, Germany
Hospital HM Nou Delfos
Barcelona, Spain
HM Sanchinarro
Madrid, Spain
Hospital Fundacion Jimenez Diaz
Madrid, Spain
Hospital universitario Virgen del Rocio
Seville, Spain
Lund University Hospital
Lund, Sweden
Karolinska University Hospital, Solna
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.